Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.

被引：0
|
作者：
Lago, Nieves Martinez
Gonzalez, Borja
Martin, Elena Gallardo
Montes, Ana Fernandez
Castineira, Antia Cousillas
Suarez, Begona Grana
Maseda, Alberto Carral
Augusto, Maria Luz Pellon
Villarroel, Paula Gonzalez
Gomez, Juan De La Camara
Fernandez, Mercedes Salgado
Lopez, Margarita Reboredo
机构：
[1] Complexo Hosp Univ Ferrol, Ferrol, Spain
[2] Hosp Univ Lucus Augusti, Lugo, Spain
[3] Alvaro Cunqueiro Hosp, Vigo, Spain
[4] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain
[5] Complejo Hosp Pontevedra, Med Oncol Dept, Pontevedra, Spain
[6] Univ Hosp A Coruna, La Coruna, Spain
[7] Hosp Univ Lucus Augusti, Med Oncol Dept, Lugo, Spain
[8] Complexo Hosp Univ Ourense, Orense, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-2370-5109; 281-5277-2560; 613-135-2370-7650-2700; 283-2494; 283-237-255; 261-492-199; 613-135-244-3829-325; 4; 3; 2; 182; 239; 16; 6; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] Real-world treatment patterns and outcomes associated with bevacizumab (bev) in metastatic colorectal cancer (mCRC).
    Saverno, Kimberly
    Walker, Mark S.
    Hennessy, Daniel
    Dhawan, Ravinder
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada
    Samawi, H. H.
    Brezden-Masley, C.
    Afzal, A. R.
    Cheung, W. Y.
    Dolley, A.
    CURRENT ONCOLOGY, 2019, 26 (05) : 319 - +
  • [43] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study
    Taieb, J.
    Falcone, A.
    Lonardi, S.
    Price, T. J.
    Bachet, J-B.
    Wyrwicz, L.
    Ciardiello, F.
    Becquart, M.
    Mounedji, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 155 - 155
  • [44] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [45] Sequential treatment with regorafenib (REG) and trifluridine/tipiracil (TAS) plus /- bevacizumab (Bev) in refractory metastatic colorectal cancer (mCRC) in community clinical practice in the USA
    Bekaii-Saab, T.
    Ahn, D.
    Yuan, C.
    Jiao, X.
    Kurtinecz, M.
    Pan, X.
    Vassilev, Z.
    Ostojic, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S442 - S442
  • [46] Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
    Ang, Choon Seong
    Low, Qin Jian
    Ho, Carol Lf
    Walsh, Robert John
    Asokumaran, Yugarajah
    Choo, Joan Re
    Chan, Gloria Hj
    Ho, Jingshan
    Ang, Yvonne
    Tan, Hon Lyn
    Yong, Wei-Peng
    Sundar, Raghav
    Chee, Cheng Ean
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting
    Shibutani, Masatsune
    En, Wang
    Okazaki, Yuki
    Kashiwagi, Shinichiro
    Fukuoka, Tatsunari
    Iseki, Yasuhito
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2021, 41 (12) : 6211 - 6216
  • [48] Real-world evidence of FTD/TPI and bevacizumab combination therapy in metastatic colorectal cancer: Survival and clinicopathological insights
    Koumarianou, A.
    Ntavatzikos, A.
    Symeonidis, D.
    Kamboli, K.
    Res, E.
    Papaxoinis, G.
    Vourli, G.
    Androulakis, N.
    Boukovinas, I.
    Oikonomopoulos, G.
    Giannakakou, M.
    Vallilas, C.
    Xynogalos, S.
    Samantas, E.
    Demiri, M.
    Souglakos, I.
    Karamouzis, M. V.
    ANNALS OF ONCOLOGY, 2024, 35 : S42 - S43
  • [49] TALLISUR Phase IV study of trifluridine/tipiracil (FTD/TPI) in patients with pre-treated metastatic Colorectal Cancer (mCRC) - subgroup analysis
    Karthaus, M.
    Weiss, L.
    Riera-Knorrenschild, J.
    Kretschmar, A.
    Welslau, M.
    Vehling-Kaiser, U.
    Pelz, H.
    Ettrich, T.
    Held, S.
    Klein, A.
    Hess, J.
    Reislaender, T.
    Heinemann, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 160 - 160
  • [50] Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study
    Karthaus, Meinolf
    Weiss, Lena
    Riera-Knorrenschild, Jorge
    Kretzschmar, Albrecht
    Welslau, Manfred
    Vehling-Kaiser, Ursula
    Pelz, Henning
    Ettrich, Thomas Jens
    Held, Swantje
    Kehrmann, Linde
    Hess, Juergen
    Reislaender, Timo
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345